4/5Protagenic Therapeutics, Inc.\new (PTIX): Late quarterly report (NT 10-Q)

Market data

Price before filing: $0.35 (2026-02-17 close, split/dividend-adjusted)
Market cap at flag: $812,649 (2026-02-18) · Latest: $1.4M (2026-10-16)

What happened next

Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.

Insider trading around this filing

90 days before the flag: no open-market insider sales or purchases reported.
30 days after: none reported.

Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-11-20 to 2026-03-20. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.

Verified excerpt

"Protagenic Therapeutics, Inc. (the "Company") will not be able to file its Quarterly Report on Form 10-Q for the period ended December 31, 2025 by the prescribed due date without unreasonable effort or expense. The Company is working to complete the remaining items as promptly as practicable but does not expect to file the Form 10-Q within the five-day extension period provided by Rule 12b-25."

Quoted from the filing. Source

What this means

The company told the SEC it could not file its quarterly report on time (Form NT 10-Q) and then missed the 5-day extension too. Repeated late filings are a stronger warning.

Status: filed late (report filed 2026-03-09)

Why this score: filed late on 2026-03-09; also within 90 days: Going-concern doubt